Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Capricor Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Capricor Therapeutics, Inc.’s stock price such as:

• Capricor Therapeutics, Inc.’s current stock price and volume
• Why Capricor Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for CAPR from analysts
• CAPR’s stock price momentum as measured by its relative strength

About Capricor Therapeutics, Inc. (CAPR)

Before we jump into Capricor Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.

Want to learn more about Capricor Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Capricor Therapeutics, Inc..

Capricor Therapeutics, Inc.’s Stock Price as of Market Close

As of May 08, 2026, 11:31 AM, CST, Capricor Therapeutics, Inc.’s stock price was $29.677.

Capricor Therapeutics, Inc. is down 12.56% from its previous closing price of $33.940.

During the last market session, Capricor Therapeutics, Inc.’s stock traded between $29.010 and $30.880. Currently, there are approximately 48.85 million shares outstanding for Capricor Therapeutics, Inc..

Capricor Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Capricor Therapeutics, Inc. Stock Price History

Capricor Therapeutics, Inc.’s (CAPR) price is currently down 11.62% so far this month.

During the month of May, Capricor Therapeutics, Inc.’s stock price has reached a high of $34.500 and a low of $29.010.

Over the last year, Capricor Therapeutics, Inc. has hit prices as high as $40.370 and as low as $4.300. Year to date, Capricor Therapeutics, Inc.’s stock is up 2.83%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Capricor Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 07, 2026, there were 2 analysts who downgraded Capricor Therapeutics, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Capricor Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Capricor Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Capricor Therapeutics, Inc. (CAPR) by visiting AAII Stock Evaluator.

Relative Price Strength of Capricor Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 07, 2026, Capricor Therapeutics, Inc. has a weighted four-quarter relative price strength of 65.02%, which translates to a Momentum Score of 98 and is considered to be Very Strong.

Want to learn more about how Capricor Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Capricor Therapeutics, Inc. Stock Price: Bottom Line

As of May 8, 2026, Capricor Therapeutics, Inc.’s stock price is $29.677, which is down 12.56% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Capricor Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.